TY - JOUR
T1 - Incident Hypertension with Antiretroviral Therapy in the OPERA Cohort
AU - Pierone, Gerald
AU - Brunet, Laurence
AU - Fusco, Jennifer S.
AU - Lackey, Philip C.
AU - Wohlfeiler, Michael B.
AU - Dieterich, Douglas T.
AU - Henegar, Cassidy
AU - Vannappagari, Vani
AU - Jones, Bryn
AU - de Ruiter, Annemiek
AU - Fusco, Gregory P.
N1 - Publisher Copyright:
© The Author(s) 2026. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PY - 2026/1/1
Y1 - 2026/1/1
N2 - Purpose of the research: To compare incident hypertension rates across antiretroviral therapy regimens among adults with HIV in routine clinical care in the US-based OPERA cohort. Major findings: The hypertension incidence rate was 4.16 per 100 person-years (95% CI: 3.75, 4.61) among 3220 ART-naïve individuals, and 4.60 (95% CI: 3.99, 5.30) among 1442 ART-experienced individuals. There was no statistically significant difference in incident hypertension between regimens at the class-level (integrase inhibitor with/without tenofovir alafenamide (TAF), boosted protease inhibitor, and non-nucleoside reverse transcriptase inhibitor) nor the drug-level (dolutegravir three-drug regimen with/without TAF, dolutegravir/lamivudine, bictegravir/emtricitabine/TAF, and boosted darunavir with TAF three-drug regimen). Conclusions: In this large cohort representing routine clinical care in the USA, classes of antiretrovirals and specific agent combinations with or without TAF were not statistically significantly associated with incident hypertension. Other factors are likely to be more important drivers of hypertension than antiretroviral therapy selection in people with HIV.
AB - Purpose of the research: To compare incident hypertension rates across antiretroviral therapy regimens among adults with HIV in routine clinical care in the US-based OPERA cohort. Major findings: The hypertension incidence rate was 4.16 per 100 person-years (95% CI: 3.75, 4.61) among 3220 ART-naïve individuals, and 4.60 (95% CI: 3.99, 5.30) among 1442 ART-experienced individuals. There was no statistically significant difference in incident hypertension between regimens at the class-level (integrase inhibitor with/without tenofovir alafenamide (TAF), boosted protease inhibitor, and non-nucleoside reverse transcriptase inhibitor) nor the drug-level (dolutegravir three-drug regimen with/without TAF, dolutegravir/lamivudine, bictegravir/emtricitabine/TAF, and boosted darunavir with TAF three-drug regimen). Conclusions: In this large cohort representing routine clinical care in the USA, classes of antiretrovirals and specific agent combinations with or without TAF were not statistically significantly associated with incident hypertension. Other factors are likely to be more important drivers of hypertension than antiretroviral therapy selection in people with HIV.
KW - antiretroviral therapy (ART)
KW - health outcomes
KW - integrase inhibitor
KW - non-Nucleoside reverse transcriptase inhibitor (NNRTI)
KW - nucleoside reverse transcriptase inhibitor (NRTI)
KW - protease inhibitor
UR - https://www.scopus.com/pages/publications/105036607655
U2 - 10.1177/23259582261445148
DO - 10.1177/23259582261445148
M3 - Article
C2 - 42023979
AN - SCOPUS:105036607655
SN - 2325-9574
VL - 25
JO - Journal of the International Association of Providers of AIDS Care
JF - Journal of the International Association of Providers of AIDS Care
ER -